Case Report : Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomyc...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver 2014-01, Vol.8 (1), p.109
Main Authors: Hye Won Lee, Moon Jae Chung, Hua Pyong Kang, Heun Choi, Youn Jeong Choi, Kyung Joo Lee, Seung Woo Lee, Seung Hyuk Han, Jin Seok Kim, Si Young Song
Format: Article
Language:Korean
Subjects:
Gemcitabine
Hemolytic-uremic syndrome
Pancreatic neoplasms
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea. (Gut Liver 2014;8:109-112)
ISSN:1976-2283